COST EFFECTIVENESS ANALYSIS OF IMPLEMENTING A SCREENING PROGRAM FOR EARLY-STAGE ALZHEIMER’S DISEASE DETECTION

Abstract

Recent advancements in Alzheimer’s Disease(AD) diagnosis have been propelled by the advent of disease-modifying therapies and the emergence of plasma-based biomarkers, notably P-tau217, which offers diagnostic accuracy comparable to cerebrospinal fluid assays and enables early disease detection.